A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
Year: 2011
Type: article
Study design: Clinical Trial
Source: Oncology
DOI: 10.1159/000327739
Institutions: Stanford Medicine, Stanford University, University of Arizona, Dana-Farber Cancer Institute, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis, Washington University in St. Louis, Mayo Clinic, Threshold Pharmaceuticals (United States), Sarcoma Oncology Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2082594665
